Mission Pharmacal Company (labeler), 2026-10-16: Uribel Tabs (Mission Pharmacal, NDC 0178-0745-01, 100 tablets) is a currently listed urinary combination tablet containing 10.8 mg methylene blue with methenamine, benzoic acid, phenyl salicylate and hyoscyamine; the SPL carries no NDA or ANDA number.
Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections.
Mission Pharmacal Company (labeler), 2026-10-16: Uribel Tabs (Mission Pharmacal, NDC 0178-0745-01, 100 tablets) is a currently listed urinary combination tablet containing 10.8 mg methylene blue with methenamine, benzoic acid, phenyl salicylate and hyoscyamine; the SPL carries no NDA or ANDA number. C8 – urinary combination product, current status. Composition per tablet from the Description field: methenamine 81.6 mg, benzoic acid 9.0 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, hyoscyamine sulfate 0.12 mg. DailyMed SPL version 5, published 2026-10-16 (label Updated date 2026-10-14). The openFDA label record for this SPL has an empty application_number field, i.e. the label metadata shows no approved application; no inference beyond that is made here. A second, near-identical Uribel label is listed under Cintex Services, LLC (set id 5ccadff1-461a-335a-e063-6394a90ad5d7, NDC 24470-967-10, effective 2026-10-05), i.e. two labelers currently publish the same Uribel formulation. Fetch route: openFDA drug/label by set_id. Also filed as MTD-099, MTD-024, MTL-085 (claims C5, C7, C8, F3). Study type: regulatory record.
